Promoted Content
Promoted Content

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OP-1250,Palbociclib

            Therapeutic Area: Oncology Product Name: OP-1250

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Olema Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 13, 2020

            Details:

            Olema Oncology will evaluate OP-1250, in combination with Pfizer's IBRANCE® in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative breast cancer. Pfizer will supply IBRANCE for the study.